PRESS RELEASE: Biotest AG: Clinical Study with Indatuximab Ravtansine (BT-062) in Multiple Myeloma shows good …

PRESS RELEASE: Biotest AG: Clinical Study with Indatuximab Ravtansine (BT-062) in Multiple Myeloma shows good Tolerability and encouraging Efficacy in Combination with Lenalidomide and Dexamethasone

DGAP-News: Biotest AG / Key word(s): Study Biotest AG: Clinical Study with Indatuximab Ravtansine (BT-062) in Multiple Myeloma shows good Tolerability and encouraging Efficacy in Combination with Lenalidomide and Dexamethasone

10.12.2013 / 01:30

=--------------------------------------------------------------------

PRESS RELEASE

Clinical Study with Indatuximab Ravtansine (BT-062) in Multiple Myeloma shows good Tolerability and encouraging Efficacy in Combination with Lenalidomide and Dexamethasone

- Efficacy and tolerability data from combination therapy study 983 presented at 55th annual conference of the American Society of Hematology (ASH)

- Good tolerability of combination therapy with indatuximab ravtansine (BT-062) at a dosage up to 100 mg/m2

- Clinical benefit seen in all evaluable patients

- Complete response observed in individual patients

More:
PRESS RELEASE: Biotest AG: Clinical Study with Indatuximab Ravtansine (BT-062) in Multiple Myeloma shows good ...

Related Posts

Comments are closed.